INDV Stock Recent News

RICHMOND, Va. , March 4, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) ("Indivior" or the "Company") today announced that, further to the announcement on December 17, 2024 of certain Director arrangements agreed with Oaktree Capital Management L.P.

British drugmaker Indivior on Thursday said it appointed Joe Ciaffoni as its new CEO, replacing current boss Mark Crossley.

RICHMOND, Va. , Feb. 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) has appointed Joe Ciaffoni, currently an Independent Non-Executive Director of the Company, as Chief Executive Officer.

Indivior PLC (INDV) Q4 2024 Earnings Call Transcript

Indivior Plc INDV stock plunged following the company's fiscal year 2025 guidance that fell short of Street expectations.

Indivior PLC (INDV) came out with quarterly earnings of $0.32 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.43 per share a year ago.

Indivior is a $970m small-cap facing to transitory headwinds resulting in extremely negative sentiment and fascinatingly low valuation. Due to the extreme mis-pricing I argue Indivior offers investors great risk/reward asymmetry with upside potential of 104% based on today's share price of $7.46. Temporary headwinds like Medicaid disenrollments, market share loses affecting Sublocade growth and ongoing antitrust litigations are priced in at a current forward EV/EBITDA of 2.3x.

Indivior PLC (LSE:INDV) shares dropped over 16% after the drug company warned that sales of its Sublocade long-lasting opioid addiction treatment were hit by a rise in rival generic versions.  Management of the group now sees lower than expected revenue from Sublocade in the third quarter and full year from a combination of faster initial adoption of a competitor's rival long-acting injectable treatment, as well as other factors.

British drugmaker Indivior on Thursday cut its 2024 net revenue forecast for the second time in three months, citing lower than expected revenues from its Sublocade treatment for opioid use disorder, sending shares 15% lower.

NEW YORK, NY / ACCESSWIRE / October 1, 2024 / If you suffered a loss on your Indivior PLC (NASDAQ:INDV) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/indivior-lawsuit-submission-form?prid=106508&wire=1 or contact Joseph E. Levi, Esq.